Advanced searches left 3/3

Blepharitis - Crossref

Summarized by Plex Scholar
Last Updated: 26 June 2022

* If you want to update the article please login/register

Efficacy and Safety of Topical Atorvastatin for the Treatment of Dry Eye Associated with Blepharitis: A Pilot Study

Aims: To clarify if topically administered atorvastatin reduces corneal fluorescein staining in dry eyes associated with blepharitis. Methods: In a prospective pilot study, ten dry eye and blepharitis patients were recruited. All patients were treated with topical atorvastatin 8 times a day for four weeks and then encouraged to continue with their current dry eye therapy. In 9 of ten patients, there was an increase in corneal fluorescein staining in the treated eye by more than 1% from baseline to completion of the trial at week 4. Term : Topical atorvastatin is a potential treatment for DEB patients.

Source link: https://doi.org/10.1159/000367851


Bevacizumab Eye Drops Vs. Intra-meibomian Gland Injection of Bevacizumab for Meibomian Gland Dysfunction-Associated Posterior Blepharitis

Aims - This research was designed to investigate the efficiency and safety of bevacizumab eye drops compared to those of an intra-meibomian gland injection of bevacizumab in patients with meibomian gland dysfunction -associated posterior blepharitis in patients with meibomian gland dysfunction – a common cause of posterior blepharitis. Study Design Methods 60 eyes of 30 patients with MGD-associated posterior blepharitis associated with lid margin telangiectasia were examined at King Chulalongkorn Memorial Hospital in a prospective, open-label, placebo-blinded trial. Patients were either randomly selected to receive lid hygiene plus 0. 05% bevacizumab eye drops or a single intra-MG injection of 2. 5% bevacizumab. In both telangiectasia grade and LMNA, there were no significant differences between groups during therapy; however, the injection group saw significant improvements relative to baseline, while in the eye drop group, only the telangiectasia grade and LMNA improved relative to baseline.

Source link: https://doi.org/10.3389/fmed.2022.895418


Improved Watershed Algorithm-Based Microscopic Images Combined with Meibomian Gland Microprobe in the Treatment of Demodectic Blepharitis

The watershed algorithm was used first to locate the target area in the image, and then the fuzzy C -means clustering algorithm was used to cluster the targets. Group E1's treatment was much higher than that of the other two groups compared to the other two groups' standard treatment methods. The groups E1 and E2's clinical sign scores after treatment were remarkably different from those before treatment. Those of group E1 demonstrated the greatest difference in terms of clinical signs and acute symptoms after therapy, indicating the best treatment result. With the latest watershed technology, the treatment of demodectic blepharitis can be enhanced, and microscopic images combined with meibomian gland microprobe had the greatest effect in the treatment of demodectic blepharitis in comparison to the traditional drug heat compress.

Source link: https://doi.org/10.1155/2022/4389659


Safety and Feasibility of Low Fluence Intense Pulsed Light for Treating Pediatric Patients with Moderate-to-Severe Blepharitis

A retrospective, noncomparative research was conducted to investigate the effectiveness and feasibility of low fluence-infused light for treating pediatric patients with moderate to severe blepharitis and evaluating potential reasons associated with the repair of meibomian glands dropout. In summary, low fluence IPL appears to be a safe and effective substitute for moderate-to-severe pediatric blepharitis, and MG dropout in younger patients is more likely to recover.

Source link: https://doi.org/10.3390/jcm11113080


Blepharitis — a review of diagnosis and management

Blepharitis is a common chronic inflammation disorder of the eyelid margin, but its precise incidence and prevalence are uncertain. It is divided anatomically into anterior blepharitis of the anterior lid margin and posterior blepharitis associated with meibomian gland dysfunction. Eye lashes can also be examined under high magnification for Demodex mite.

Source link: https://doi.org/10.12968/ijop.2012.3.4.150


Statin Use Is Associated With a Lower Risk of Blepharitis: A Population-Based Study

Background Blepharitis is a common eye disease that may be ignored by physicians and consultants alike. Increased inflammatory marker levels, which is a common cause of blepharitis, is believed to be connected to increased inflammatory marker levels that can alter the composition of lipids produced by the eyelids' sebaceous glands and ultimately cause tear film instability. Methods This is a retrospective, population-based analysis based on National Health Insurance Database results from a 14-year period. Results As the comparison group, a total of 67,014 patients using statins were included in the study cohort, while 268,056 patients who did not use statins were included as the comparison group. 4. 0 percent with statin therapy and 3. 7 percent without statin therapy, respectively. Patients who used statins had a reduced risk of developing blepharitis [adjusted hazard ratio : 0. 746, p 0. 001], compared to those who did not.

Source link: https://doi.org/10.3389/fmed.2022.820119


Efficacy and safety of mercuric oxide in the treatment of bacterial blepharitis

In the treatment of eyelid infections, i. e. , bacterial blepharitis, a double-masked, placebo-controlled, randomized study was conducted to determine the safety and clinical quality of 1% mercuric oxide ophthalmic ointment in the treatment of eyelid infections, i. e. , bacterial blepharitis. Eyelid infection patients with bacterial counts and clinical signs were treated twice daily for 7 days.

Source link: https://doi.org/10.1128/aac.34.4.610


The Efficacy of Kohl (Surma) and Erythromycin in Treatment of Blepharitis: An Open-Label Clinical Trial

Blepharitis is a common and chronic condition of eyelid inflammation. Blepharitis medication is intended to reduce symptoms by antibacterial use. Kohl is one of the most common treatments of eyelid disease in conventional medicine. Patients in a third eye were randomized to receive kohl in one eye contralateral and erythromycin ointment in another eye for 90 days. Despite randomization, there was a significant difference between the intervention and control eyes in the baseline mean clinical result. The degree of reduction of related signs and symptoms in the eyes treated with kohl was significantly higher than that in the control group's: symptoms and clinical signs. The mean difference of sign and symptom was 2. 4 and 1. 75, respectively, indicating a strong influence. Cohen's d statistic for mean difference of sign and symptom was 2. 4 and 1. 75, respectively, indicating a strong correlation. The degree of improvement in the eyes treated with kohl was much greater than that in control eyes.

Source link: https://doi.org/10.1155/2022/6235857

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions